Does Medicare Cover Wegovy in 2026, and What Will You Pay?

Wegovy has one of the most complicated Medicare coverage stories of any drug on the market right now. The short version: Medicare could not cover weight-loss drugs under a 2003 statutory prohibition, but two things changed that picture. First, the FDA approved Wegovy for cardiovascular risk reduction in March 2024, giving a non-weight-loss indication that Medicare can cover under Part D. Second, CMS launched the Medicare GLP-1 Bridge as a demonstration program that bypasses the 2003 ban via executive authority, effective July 1, 2026, with a flat $50 monthly copay.

The BALANCE Model, a broader CMS demonstration designed to expand GLP-1 access through Medicare Part D plan sponsors, was indefinitely delayed on April 21, 2026. CMS cited insufficient plan participation: Part D plan sponsors covering at least 80% of beneficiaries needed to apply, and that threshold was not met. CMS confirmed on April 30 that the Bridge extension through December 31, 2027 would serve as the interim solution. The Medicaid component of BALANCE proceeds separately, running May 2026 through December 2031 for participating states.

Looking ahead to 2027: CMS negotiated a Maximum Fair Price of $385 per month for Wegovy under IRA Round 2, down 71% from the $1,349 list price. This takes effect January 1, 2027. That negotiated price applies across all covered indications when billed through Medicare Part D. Enrollees who qualify for Wegovy coverage under the cardiovascular indication will see their plan cost-share calculated against the lower $385 price, not the list price, making 2027 a significant inflection point for Medicare affordability of semaglutide.

What Wegovy Medicare Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same wegovy medicare can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Wegovy is a self-administered outpatient medication, which means it is almost always dispensed at a pharmacy rather than administered in a hospital setting. Unlike infused biologics or chemotherapy, Wegovy does not generate a hospital facility charge or a Medicare Part B billing event. The cost question for Wegovy is almost entirely a pharmacy and insurance formulary question, not a hospital billing question.

That said, there is a pricing markup issue at the pharmacy and plan formulary level that mirrors the hospital markup problem. The list price of $1,349 per month reflects Novo Nordisk's Wholesale Acquisition Cost (WAC). Pharmacy benefit managers negotiate rebates from Novo Nordisk that reduce what plans actually pay, but those rebates historically flow to insurers and PBMs rather than directly to patients at the counter. The IRA negotiated price of $385, effective 2027, is the first time Medicare patients will see a price floor that actually reflects something closer to net cost.

The Medicare GLP-1 Bridge at $50 per month operates as a carve-out outside the standard Part D benefit. CMS contracts with Humana as the Bridge administrator, and the prescription flows through a separate prior authorization and fulfillment channel. One consequence: the $50 Bridge copay does not accumulate toward your $2,100 annual Part D out-of-pocket cap. Patients on multiple Part D drugs should model both pathways: if your other drug costs are high, standard Part D coverage with the IRA-negotiated price (from 2027) may result in a lower total annual cost than the Bridge.

Patient Assistance Programs

Novo Nordisk runs several savings programs for Wegovy. The NovoCare Savings Card is for commercially insured patients. The NovoCare Pharmacy self-pay program offers a cash price for uninsured patients. The standard Novo Nordisk PAP (for uninsured patients below income limits) currently does not list Wegovy on its covered medication roster, though that may change. Check novocare.com for the most current eligibility:

Medicare Part D

Wegovy is covered under Medicare Part D under two conditions. First, under the standard Part D benefit, Wegovy is covered when prescribed for cardiovascular risk reduction (the FDA indication approved March 2024) in adults with established cardiovascular disease who are overweight or obese. The weight-loss statutory exclusion under 42 U.S.C. 1395w-102(e)(2)(A) does not apply to this cardiovascular indication. Standard Part D coverage means your plan's formulary tier, deductible, and the $2,100 annual out-of-pocket cap all apply normally.

Second, the Medicare GLP-1 Bridge (effective July 1, 2026 through December 31, 2027) is a separate CMS demonstration program that covers Wegovy at $50 per month for enrollees who meet BMI criteria, regardless of whether they have cardiovascular disease. The three eligibility categories are: BMI 35 or higher (no additional conditions required); BMI 30 or higher with heart failure, uncontrolled hypertension, or Stage 3 or higher chronic kidney disease; or BMI 27 or higher with pre-diabetes, history of heart attack or stroke, or symptomatic sleep apnea. Eligibility is confirmed by a prescriber attestation submitted through prior authorization to the CMS contractor Humana.

Key 2026 Medicare limitation: the $50 Bridge copay does not count toward the $2,100 annual Part D out-of-pocket cap and does not count toward the Part D deductible. Low-Income Subsidy (Extra Help) enrollees are not eligible for cost-sharing assistance under the Bridge at this time. The BALANCE Model for Part D, which would have provided GLP-1 coverage through standard Part D plans at a CMS-negotiated $245 net price per month, was indefinitely delayed by CMS on April 21, 2026 after insufficient plan sponsor participation.

Common Wegovy Medicare Billing Errors

Because Wegovy Medicare coverage spans two programs with different billing channels, billing errors are more common in 2026 than for other Part D drugs. Check your Explanation of Benefits for these issues:

• Bridge copay incorrectly applied toward the $2,100 Part D annual out-of-pocket cap (the $50 Bridge copay legally cannot count toward this limit)
• Claim submitted to standard Part D plan instead of the Bridge administrator (Humana), resulting in denial because the Part D plan does not cover Wegovy for weight loss under the statutory exclusion
• Prior authorization submitted without prescriber BMI attestation, resulting in Bridge denial even when the patient meets clinical criteria
• Cardiovascular indication claim denied because the diagnosis code on file is obesity-related rather than cardiovascular (confirm ICD-10 codes for established CVD are on the claim)
• NovoCare Savings Card applied to a Medicare enrollee's claim (the NovoCare card is not valid for Medicare patients and can trigger a federal anti-kickback issue if applied)

Frequently Asked Questions